Effect of Feminizing Hormone Therapy on QTc Interval: A Secondary Analysis of a Randomized Clinical Trial

Lachlan M Angus; Tina Lin; Shalem Y Leemaqz; Ada S Cheung

doi:10.1001/jamanetworkopen.2024.3994

Effect of Feminizing Hormone Therapy on QTc Interval: A Secondary Analysis of a Randomized Clinical Trial

JAMA Netw Open. 2024 Mar 4;7(3):e243994. doi: 10.1001/jamanetworkopen.2024.3994.

Authors

Lachlan M Angus¹, Tina Lin², Shalem Y Leemaqz³, Ada S Cheung¹

Affiliations

¹ Trans Health Research, Department of Medicine, University of Melbourne, Victoria, Australia.
² Department of Cardiology, Austin Health, Victoria, Australia.
³ College of Medicine and Public Health, Flinders University, South Australia, Australia.

No abstract available

Plain language summary

This secondary analysis of a randomized clinical trial investigates the effect of spironolactone and cyproterone acetate hormone therapy on the QT interval corrected for heart rate among transgender women and nonbinary or transfeminine individuals.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Electrocardiography*
Hormones*
Humans

Substances

Hormones